ECSP23019419A - Proceso e intermedios para preparar un inhibidor de jak1 - Google Patents
Proceso e intermedios para preparar un inhibidor de jak1Info
- Publication number
- ECSP23019419A ECSP23019419A ECSENADI202319419A ECDI202319419A ECSP23019419A EC SP23019419 A ECSP23019419 A EC SP23019419A EC SENADI202319419 A ECSENADI202319419 A EC SENADI202319419A EC DI202319419 A ECDI202319419 A EC DI202319419A EC SP23019419 A ECSP23019419 A EC SP23019419A
- Authority
- EC
- Ecuador
- Prior art keywords
- intermediates
- prepare
- jak1 inhibitor
- jak1
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Health & Medical Sciences (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067062P | 2020-08-18 | 2020-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23019419A true ECSP23019419A (es) | 2023-04-28 |
Family
ID=77693614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202319419A ECSP23019419A (es) | 2020-08-18 | 2023-03-16 | Proceso e intermedios para preparar un inhibidor de jak1 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11897889B2 (https=) |
| EP (1) | EP4200278A1 (https=) |
| JP (1) | JP7778135B2 (https=) |
| KR (1) | KR20230095923A (https=) |
| CN (1) | CN117043152A (https=) |
| AR (1) | AR123268A1 (https=) |
| AU (1) | AU2021329301A1 (https=) |
| BR (1) | BR112023002939A2 (https=) |
| CA (1) | CA3192055A1 (https=) |
| CL (2) | CL2023000482A1 (https=) |
| CO (1) | CO2023003286A2 (https=) |
| CR (1) | CR20230130A (https=) |
| EC (1) | ECSP23019419A (https=) |
| IL (1) | IL300557A (https=) |
| MX (1) | MX2023002035A (https=) |
| PE (1) | PE20231308A1 (https=) |
| TW (1) | TWI904215B (https=) |
| WO (1) | WO2022040172A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| IL300557A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK1 inhibitor |
| PE20231743A1 (es) | 2020-08-18 | 2023-10-31 | Incyte Corp | Proceso e intermediarios para preparar un inhibidor de jak |
| US12071439B2 (en) | 2021-07-12 | 2024-08-27 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
| CN117903032A (zh) * | 2022-10-12 | 2024-04-19 | 重庆博腾制药科技股份有限公司 | 一种巴瑞替尼中间体的制备方法及制备巴瑞替尼的方法 |
| CN120882718A (zh) * | 2023-03-17 | 2025-10-31 | 北京普祺医药科技股份有限公司 | 吡咯并嘧啶化合物或其可药用盐的制备方法 |
| CN117603193A (zh) * | 2023-12-20 | 2024-02-27 | 杭州澳赛诺生物科技有限公司 | 一种β-氰基吡唑类化合物的合成方法 |
| CN121135621A (zh) * | 2024-06-07 | 2025-12-16 | 上海长森药业有限公司 | 一种jak抑制剂的制备方法及其中间体 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB812366A (en) | 1955-08-18 | 1959-04-22 | Wellcome Found | Improvements in and relating to derivatives of pyrimidine and the preparation thereof |
| US5102904A (en) | 1989-12-08 | 1992-04-07 | American Cyanamid Company | N-oxygenated arylpyrrole insecticidal, acaricidal and nematicidal agents and use thereas |
| EP1411933A1 (en) * | 2001-08-03 | 2004-04-28 | SmithKline Beecham Corporation | Alpha-ketoamide derivatives as cathepsin k inhibitors |
| WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
| JP4842929B2 (ja) | 2004-05-27 | 2011-12-21 | ファイザー・プロダクツ・インク | 癌治療に有用なピロロピリミジン誘導体 |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| EP1913000B1 (en) | 2005-07-29 | 2012-01-11 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| CN2928286Y (zh) | 2006-01-06 | 2007-08-01 | 水城钢铁（集团）有限责任公司 | 预入口导卫装置 |
| KR101450535B1 (ko) | 2006-02-02 | 2014-10-14 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｅ１ 활성화 효소의 억제제 |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| WO2009016460A2 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| UA104849C2 (uk) | 2007-11-16 | 2014-03-25 | Інсайт Корпорейшн | 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus |
| HUE029767T2 (en) * | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| TWI720517B (zh) | 2009-01-15 | 2021-03-01 | 美商英塞特公司 | 製造ｊａｋ抑制劑之方法及相關中間化合物 |
| JP2012523405A (ja) | 2009-04-10 | 2012-10-04 | ファイザー・インク | ４，５−ジヒドロ−１ｈ−ピラゾール化合物およびその薬学的使用 |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| SI2432472T1 (sl) | 2009-05-22 | 2019-11-29 | Incyte Holdings Corp | 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EA021478B1 (ru) | 2009-10-09 | 2015-06-30 | Инсайт Корпорейшн | ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА |
| CN106220623A (zh) | 2009-11-06 | 2016-12-14 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
| ES2627911T3 (es) | 2009-11-18 | 2017-08-01 | Plexxikon, Inc. | Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer |
| JP5858434B2 (ja) | 2010-02-18 | 2016-02-10 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体 |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| AU2012295802B2 (en) | 2011-08-12 | 2017-03-30 | Nissan Chemical Industries, Ltd. | Tricyclic heterocyclic compounds and JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| EP2628730B1 (en) | 2012-02-16 | 2017-12-06 | Noxell Corporation | Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| CN103044286B (zh) * | 2013-01-25 | 2015-04-08 | 重庆紫光化工股份有限公司 | 丙二腈的合成方法 |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| HUE033587T2 (hu) | 2013-05-17 | 2017-12-28 | Incyte Corp | Bipirazol-származékok mint JAK inhibitorok |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| EP3183253B1 (en) | 2014-08-21 | 2018-06-27 | ratiopharm GmbH | Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid |
| EP3183252B1 (en) | 2014-08-21 | 2021-05-12 | ratiopharm GmbH | Oxalate salt of ruxolitinib |
| WO2016035014A1 (en) | 2014-09-01 | 2016-03-10 | Sun Pharmaceutical Industries Limited | Processes for the preparation of ruxolitinib phosphate |
| WO2016063294A2 (en) | 2014-10-20 | 2016-04-28 | Msn Laboratories Private Limited | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof |
| JP6038111B2 (ja) * | 2014-12-27 | 2016-12-07 | ヤマサ醤油株式会社 | 多置換７−デアザプリン誘導体合成のための２，６−ジクロロ−８−ヨード−７−デアザプリン |
| MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| CA2928286A1 (en) | 2015-04-28 | 2016-10-28 | Signa S.A. De C.V. | Solid form of ruxolitinib phosphate |
| CN106397443A (zh) | 2015-07-17 | 2017-02-15 | 浙江九洲药业股份有限公司 | 一种吡咯嘧啶类衍生物中间体的制备方法 |
| CZ2015575A3 (cs) | 2015-08-26 | 2017-03-08 | Zentiva, K.S. | Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava |
| EP3394080B1 (en) | 2015-12-23 | 2023-06-07 | The University Of British Columbia | Lipid-linked prodrugs |
| US10562904B2 (en) | 2015-12-31 | 2020-02-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Synthesis process of ruxolitinib |
| CZ201629A3 (cs) | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
| CN107513069A (zh) | 2016-06-16 | 2017-12-26 | 正大天晴药业集团股份有限公司 | 手性吡咯并嘧啶化合物的制备方法 |
| IN201641026603A (https=) | 2016-08-04 | 2018-02-09 | ||
| CN107722012B (zh) | 2016-08-11 | 2020-05-29 | 斯福瑞（南通）制药有限公司 | 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法 |
| CN107759601B (zh) | 2016-08-23 | 2020-09-11 | 苏州旺山旺水生物医药有限公司 | 一种jak抑制剂及其盐的制备方法 |
| CN107759623B (zh) | 2016-08-23 | 2020-08-14 | 苏州旺山旺水生物医药有限公司 | Jak抑制剂的中间体及其制备方法 |
| US20190263796A1 (en) | 2016-09-23 | 2019-08-29 | Cellipse | Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases |
| CN109651424B (zh) | 2017-10-11 | 2021-01-22 | 新发药业有限公司 | 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法 |
| CN113149993A (zh) | 2017-12-01 | 2021-07-23 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
| US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| CN112041303A (zh) | 2018-05-21 | 2020-12-04 | Pi工业有限公司 | 制备取代的杂环化合物的方法 |
| AU2020219797B2 (en) | 2019-02-06 | 2025-10-16 | Sun Pharmaceutical Industries, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| CN110724145A (zh) | 2019-11-01 | 2020-01-24 | 廖文杰 | 一种医药中间体4-氯吡咯并嘧啶的合成方法 |
| CN116761792A (zh) * | 2020-08-18 | 2023-09-15 | 因赛特公司 | 用于制备jak抑制剂的方法和中间体 |
| IL300557A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK1 inhibitor |
| PE20231743A1 (es) | 2020-08-18 | 2023-10-31 | Incyte Corp | Proceso e intermediarios para preparar un inhibidor de jak |
| US12071439B2 (en) | 2021-07-12 | 2024-08-27 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
| CN113480546A (zh) | 2021-07-30 | 2021-10-08 | 江苏君若药业有限公司 | 巴瑞克替尼及其衍生物的制备 |
-
2021
- 2021-08-17 IL IL300557A patent/IL300557A/en unknown
- 2021-08-17 JP JP2023512178A patent/JP7778135B2/ja active Active
- 2021-08-17 PE PE2023000303A patent/PE20231308A1/es unknown
- 2021-08-17 US US17/404,461 patent/US11897889B2/en active Active
- 2021-08-17 CA CA3192055A patent/CA3192055A1/en active Pending
- 2021-08-17 WO PCT/US2021/046286 patent/WO2022040172A1/en not_active Ceased
- 2021-08-17 MX MX2023002035A patent/MX2023002035A/es unknown
- 2021-08-17 TW TW110130370A patent/TWI904215B/zh active
- 2021-08-17 CR CR20230130A patent/CR20230130A/es unknown
- 2021-08-17 AR ARP210102307A patent/AR123268A1/es unknown
- 2021-08-17 CN CN202180068687.0A patent/CN117043152A/zh active Pending
- 2021-08-17 EP EP21766776.5A patent/EP4200278A1/en active Pending
- 2021-08-17 AU AU2021329301A patent/AU2021329301A1/en active Pending
- 2021-08-17 KR KR1020237009250A patent/KR20230095923A/ko active Pending
- 2021-08-17 BR BR112023002939A patent/BR112023002939A2/pt unknown
-
2023
- 2023-02-16 CL CL2023000482A patent/CL2023000482A1/es unknown
- 2023-03-16 CO CONC2023/0003286A patent/CO2023003286A2/es unknown
- 2023-03-16 EC ECSENADI202319419A patent/ECSP23019419A/es unknown
- 2023-12-19 US US18/545,545 patent/US12428426B2/en active Active
-
2024
- 2024-10-17 CL CL2024003156A patent/CL2024003156A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230130A (es) | 2023-07-13 |
| KR20230095923A (ko) | 2023-06-29 |
| JP7778135B2 (ja) | 2025-12-01 |
| CL2023000482A1 (es) | 2023-09-29 |
| AR123268A1 (es) | 2022-11-16 |
| CA3192055A1 (en) | 2022-02-24 |
| TWI904215B (zh) | 2025-11-11 |
| AU2021329301A1 (en) | 2023-04-13 |
| WO2022040172A1 (en) | 2022-02-24 |
| IL300557A (en) | 2023-04-01 |
| EP4200278A1 (en) | 2023-06-28 |
| TW202212341A (zh) | 2022-04-01 |
| MX2023002035A (es) | 2023-06-12 |
| US20240246982A1 (en) | 2024-07-25 |
| BR112023002939A2 (pt) | 2023-04-25 |
| US20220056034A1 (en) | 2022-02-24 |
| US12428426B2 (en) | 2025-09-30 |
| CL2024003156A1 (es) | 2025-02-28 |
| JP2023538614A (ja) | 2023-09-08 |
| CO2023003286A2 (es) | 2023-06-09 |
| US11897889B2 (en) | 2024-02-13 |
| CN117043152A (zh) | 2023-11-10 |
| PE20231308A1 (es) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23019419A (es) | Proceso e intermedios para preparar un inhibidor de jak1 | |
| CO2023003281A2 (es) | Proceso e intermediarios para preparar un inhibidor de jak | |
| CL2020000407A1 (es) | Proceso para preparar compuesto inhibidor de bet. (solicitud divisional 201803702). | |
| UY38837A (es) | Proceso de elaboración de moduladores de cftr | |
| AR111960A1 (es) | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación | |
| CO2021008681A2 (es) | Inhibidor de 15-pgdh | |
| BR112019004161A2 (pt) | novo promotor e uso do mesmo | |
| AR111304A1 (es) | Métodos para sintetizar un inhibidor de mcl-1 | |
| EP4484435A3 (en) | Processes and intermediates for preparing mcl1 inhibitors | |
| BR112023018095A2 (pt) | Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo | |
| MX2019010642A (es) | Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos. | |
| AR105967A1 (es) | Sales de un inhibidor de pim quinasa | |
| BR112019000026A2 (pt) | sais de ácido diorganilfosfínico, método para sua produção e seu uso | |
| CL2024000609A1 (es) | Proceso para sintetizar derivados de naftiridina y compuestos intermedios de los mismos. | |
| MX2025003091A (es) | Metodo para producir derivado de heterociclideno acetamida | |
| MX2018014323A (es) | Metodo para la fabricacion de una lamina de acero twip que tiene una matriz austenitica. | |
| AR122505A1 (es) | Procesos para preparar un inhibidor de jak1 | |
| PE20221009A1 (es) | Sintesis de un inhibidor de calicreina plasmatica a escala de proceso | |
| MX2018014322A (es) | Metodo para la fabricacion de una lamina de acero recuperada que tiene una matriz austenitica. | |
| ECSP22046595A (es) | Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina | |
| MX2022003879A (es) | Proceso para elaborar acidos alcansulfonicos. | |
| CR20240157A (es) | Nuevas sales de trimetazidina | |
| MX2022006178A (es) | Composiciones que comprenden tricianohexano. | |
| BR112021026624A2 (pt) | Processo para a fabricação de 3,5-difluoro-benzilamida de ácido (s)-3-hidróxi-1-(1h-indol-5-il)-2-oxo-pirrolidina-3-carboxílico | |
| CL2023000006A1 (es) | Composición, proceso y uso |